9 April 2024
Maxwellia revolutionises menstrual health category in pharmacy with the introduction of Evana® and Ultravana®
Alderley Park, Cheshire, UK - April 08, 2024 - Women’s health champion Maxwellia is pleased to announce the availability of Evana® Heavy Period Relief 500mg tablets (tranexamic acid) and Ultravana® Period Pain Relief 250mg tablets (naproxen) to help women manage heavy and...
20 March 2024
Sight and Sound announces partnership with Speaksee
Sight and Sound has joined forces with Dutch technology company Speaksee to deliver cutting-edge solutions in the UK. Speaksee’s innovative technology allows for real-time transcription of conversations, making it easier for individuals with hearing loss to follow along and...
7 March 2024
Oxford BioTherapeutics announces launch of enhanced discovery platform, OGAP®-Verify, at World ADC Conference 2024
• OGAP®-Verify allows for significantly enhanced sensitivity and specificity for improved target selection, dramatically accelerating drug target discovery … • OGAP-Verify is now more sensitive than Immunohistochemistry (IHC), measuring membrane proteins as low as 50...
5 March 2024
Pill Connect announces its acceptance onto the leading CDMO’s smart packaging supply program
Pill Connect, the smart dosing device company, today announces its acceptance onto the leading CDMO’s (Contract development and manufacturing organization) smart packaging supply program. Following an intensive validation process, the device has passed the product qualification...
21 February 2024
Maxwellia announces the launch of LoviTest™
Alderley Park, Cheshire, UK - February 21, 2024 - Maxwellia is delighted to announce the launch of LoviTest™, a convenient at-home STI testing service for chlamydia and gonorrhoea. LoviTest marks the latest addition to Maxwellia's direct-to-consumer (D2C) sexual health offering...
20 February 2024
LoviOne® crowned winner of the Pharmacy Product of the Year - Consumers’ Choice 2024
LoviOne®, Maxwellia’s emergency contraceptive pill brand, has been crowned winner of the Pharmacy Product of the Year Consumers’ Choice 2024. The highly anticipated Pharmacy Product of the Year awards are voted on by independent pharmacies and their customers, allowing them to...
14 February 2024
Innovation funding boost for blister prevention firm
The Wirral-based business behind PelliTec blister prevention technology has secured grant funding from Innovate UK. Building on the success of former Innovate UK programmes, like Women in Innovation and Young Innovators, the innovation agency is awarding £6.2m to firms...
18 January 2024
Oxford BioTherapeutics announces first patient dosed with lead candidate, OBT076, in Phase 1b trial in adenoid cystic carcinomas of the head and neck
OBT, in collaboration with GORTEC, is evaluating OBT076, an innovative Antibody Drug Conjugate (ADC) targeting CD205 receptor that is highly overexpressed in solid and liquid tumors … Oxford, UK, San Jose, Calif., 18 January 2024 - Oxford BioTherapeutics (‘OBT’), a clinical...
8 January 2024
Monument Therapeutics announces the grant of U.S. patent supporting MT1988 program for schizophrenia
Manchester, UK, January 4, 2024 – Monument Therapeutics, a stratified medicine company developing novel treatments for areas of high unmet need in psychiatry and neurology, today announced that the United States Patent and Trademark Office (“USPTO”) has granted U.S. patent...
30 November 2023
Oxford BioTherapeutics announces partner Boehringer Ingelheim received U.S. FDA Fast Track Designation for BI 764532 for potential treatment of advanced or metastatic large-cell neuroendocrine carcinoma of the lung
• BI 764532 is an investigational T-cell engager that redirects T cells towards cancer cells expressing the DLL3 protein … • DLL3 antigen was discovered using OBT’s proprietary OGAP® drug discovery platform … • This is the third Fast Track designation for BI 764532 … Oxford...